What is the optimal management strategy for an adult with autosomal dominant polycystic kidney disease (ADPKD), including blood pressure control with an ACE inhibitor or angiotensin‑II receptor blocker, disease‑modifying therapy with tolvaptan, lifestyle measures, screening for extra‑renal manifestations, complication management, regular monitoring, and planning for renal replacement therapy?

Optimal Management of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

All adults with ADPKD require aggressive blood pressure control with ACE inhibitors or ARBs as first-line therapy, targeting systolic BP <120 mmHg (or <110/75 mmHg if age <50 years with eGFR >60 and Mayo Class 1C-1E), combined with tolvaptan for those at high risk of rapid progression (Mayo Class 1C-1E or eGFR decline >3 mL/min/1.73m²/year), alongside mandatory lifestyle modifications including salt restriction to ≤2000 mg/day and hydration >2.5 L/day. 1, 2

Blood Pressure Management: The Foundation of Treatment

Target Blood Pressure

• Systolic BP <120 mmHg for most adults aged ≥50 years or with CKD stages 3-5 1
• More aggressive target of <110/75 mmHg for younger patients (<50 years) with preserved kidney function (eGFR >60 mL/min/1.73m²) and rapid progression (Mayo Class 1C-1E) 2
• Hypertension affects 70-80% of ADPKD patients and precedes loss of renal function 2

First-Line Antihypertensive Agents

• ACE inhibitors or ARBs are mandatory as first-line agents for all ADPKD patients, providing renoprotection beyond blood pressure lowering alone 1, 3
• These agents slow disease progression independent of their blood pressure effects 3
• Continue ACE inhibitor/ARB therapy even if additional agents are needed to reach BP targets 1

Monitoring Strategy

• Annual clinic blood pressure measurements at minimum for all patients, including asymptomatic at-risk individuals who have deferred diagnostic testing 4
• Ambulatory blood pressure monitoring (ABPM) is superior to clinic measurements and should be used routinely, as 16-18% of children with ADPKD have isolated nocturnal hypertension that clinic measurements miss 4
• ABPM is particularly valuable for detecting masked hypertension and avoiding unnecessary treatment of white-coat hypertension 4

Disease-Modifying Therapy with Tolvaptan

Patient Selection Criteria

Tolvaptan should be offered to adults with:

• CKD stages 1-3 at treatment initiation 1
• AND evidence of rapid progression defined as:
  • Mayo Imaging Classification 1C, 1D, or 1E 1, 2
  • OR eGFR decline >3 mL/min/1.73m²/year 2

Expected Benefits

• Slows eGFR decline by 0.98-1.27 mL/min/1.73m²/year 2
• Reduces total kidney volume growth by 2.7% annually 1
• Delays onset of kidney failure, particularly important for Mayo Class 1C-1E patients who otherwise progress to kidney replacement therapy at mean ages of 58.4,52.5, and 43.4 years respectively 2

Safety Monitoring

• Hepatotoxicity risk requires regular monitoring: obtain liver function tests at baseline, monthly for 18 months, then every 3 months 1
• Patients must be able to tolerate aquaresis (increased urine output) and maintain adequate fluid intake 1
• 36.4% develop grade III/IV adverse events and 22.7% discontinue due to unacceptable toxicity in real-world practice 5

Special Considerations

• Do not use routinely in children; off-label use can be considered only in selected cases at specialized centers 4
• Patients with rapid kidney function decline may show worse response 5

Lifestyle Modifications: Non-Negotiable Components

Dietary Sodium Restriction

• Limit sodium intake to ≤2000 mg/day 1, 2
• Higher urinary sodium excretion directly correlates with kidney growth and disease progression 6
• Measure 24-hour urinary sodium to assess compliance, as urinary sodium is associated with increased risk of ≥50% eGFR decline, ESRD, or death 6
• Achieving this target often requires dietitian support 6

Hydration

• Maintain fluid intake >2.5 L/day 1, 2
• ADPKD patients have heightened sensitivity to water deprivation and generate higher endogenous vasopressin levels 6
• Adequate hydration mitigates vasopressin-driven disease mechanisms 6

Additional Lifestyle Measures

• Moderate-intensity regular exercise 1
• Weight management to avoid obesity 1, 2
• Avoid excessive caffeine 1
• Smoking cessation is essential 4
• Avoid nephrotoxic medications, particularly chronic NSAIDs which cause renal adverse effects 7

Screening for Extra-Renal Manifestations

Hepatic Cysts

• >90% of patients >35 years develop liver cysts 2
• Do not perform routine screening in asymptomatic patients 4
• Obtain liver imaging only at initial presentation if alternative diagnoses are being considered, or if acute abdominal pain develops 4
• Women should avoid high-estrogen contraceptives due to potential exacerbation of liver disease 4

Intracranial Aneurysms

• 9-14% of ADPKD patients develop intracranial aneurysms with rupture rate of 0.57 per 1000 patient-years 2
• Screen only if additional risk factors present: positive family history of aneurysm or subarachnoid hemorrhage, previous intracranial aneurysm, or high-risk profession 4
• Do not perform routine screening in children as rupture is exceedingly rare in childhood 4

Cardiac Manifestations

• Mitral valve prolapse occurs in 12% of children with ADPKD, but this is within the range for healthy children 4
• Do not perform echocardiographic screening in children without a heart murmur 4

Complication Management

Urinary Tract Infections

• Incidence is 15-25% in children and 21-75% in adults, markedly higher than general population 7
• Obtain both urine AND blood cultures before initiating antibiotics in any febrile ADPKD patient 6, 7
• Standard 7-day antibiotic course (nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin) for uncomplicated UTI 7
• Do not treat asymptomatic bacteriuria 7

Infected Kidney Cysts: A Distinct Entity

Suspect cyst infection when:

• CRP ≥50 mg/L OR WBC >11 × 10⁹/L 7
• PLUS fever >38°C, acute flank/abdominal pain, and localized tenderness 7

Diagnostic approach:

• Blood cultures are essential (bacteremia occurs in ~60% of cases) 7
• Perform renal ultrasound, CT, or MRI to exclude cyst hemorrhage or nephrolithiasis 7
• When inflammatory markers are elevated with fever and focal pain, obtain ¹⁸F-FDG PET-CT for definitive cyst localization 7

Treatment differs fundamentally from UTI:

• Requires 4-6 weeks of lipid-soluble antibiotics (trimethoprim-sulfamethoxazole or fluoroquinolones) 7
• Start empirically with third-generation IV cephalosporin ± fluoroquinolone targeting E. coli (74% of cases) 7
• Fluoroquinolones are preferred for superior cyst penetration, but discuss increased risk of tendinopathy and aortic aneurysm/dissection with patients 7
• Consider percutaneous drainage for cysts >8 cm, immunocompromised patients, or sepsis 7

Hematuria

• Occurs in 5-15% of children and 64% of adults 6
• Gross hematuria before age 30-35 years predicts poorer renal survival 6
• Document presence and timing for prognostic purposes 6

Pain Management

• Avoid chronic NSAIDs due to renal adverse effects 7
• Use alternative analgesics (acetaminophen, opioids for severe pain) 7

Regular Monitoring Protocol

Renal Function Assessment

• Annual measurement of serum creatinine and eGFR for all patients 1
• Calculate annual rate of eGFR decline to identify rapid progressors (>3 mL/min/1.73m²/year) 2

Proteinuria Screening

• Measure albumin-to-creatinine ratio (ACR) annually 6
• Do not rely on dipstick testing as it lacks sensitivity to detect mild albuminuria typical in ADPKD (median ACR 3.2 mg/mmol) 6
• 49% have moderate albuminuria (≥3 mg/mmol); only 3.4% have severe albuminuria (≥30 mg/mmol) 6
• Proteinuria serves as both a marker and pathogenic factor for progression 6

Total Kidney Volume Assessment

• Use Mayo Imaging Classification to stratify progression risk 2
• Mayo Class 1C-1E indicates rapid growth (6-10%/year) versus 1A-1B (1-5%/year) 2
• Repeat imaging to assess response to therapy and refine prognosis 1

Planning for Renal Replacement Therapy

Timing and Modality

• Approximately 50% of ADPKD patients require kidney replacement therapy by age 62 years 2
• Preemptive living-donor kidney transplantation is the preferred treatment for kidney failure 1
• Begin transplant evaluation and living donor search when eGFR approaches 20 mL/min/1.73m² 1

Native Nephrectomy

• Perform native nephrectomy ONLY for specific indications: 1
  • Severe symptoms (intractable pain, early satiety)
  • Recurrent cyst infections
  • Suspicion of renal cell carcinoma
  • Insufficient space for transplant kidney
• Do not perform routine prophylactic nephrectomy 1

Special Populations

Children and Young Adults

• For asymptomatic minors at risk, ongoing surveillance OR immediate diagnostic screening are equally valid 4
• Ultrasonography is the radiological method of choice; ≥1 cyst in an at-risk child is highly suggestive of ADPKD, but negative scan cannot rule out disease 4
• Monitor for hypertension (preferably by ABPM) and albuminuria even if disease status is unknown 4
• Strongly encourage low dietary salt intake as recommended for all children 4
• Genetic testing is recommended for infants with very-early-onset symptomatic disease and children with negative family history and progressive disease 4
• Transition to adult care should follow best-practice guidelines to avoid discontinuity of care 4

Pregnancy

• Women with ADPKD can generally have successful pregnancies, but require close monitoring for hypertension and preeclampsia 4
• Genetic counseling should address 50% transmission risk to offspring 4

Psychosocial Support

• Encourage families to openly discuss disease and genetic risks with age-appropriate information 4
• Address psychological issues including genetic guilt and anxiety about future disease course 4
• Provide positive messages: "you are not ill," "you have time to influence outcome by preventive measures" 4
• Contact with affected peers via patient communities should be encouraged 4